Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Sanofi/Regeneron’s Dupixent gets US label update for atopic dermatitis

Dupixent’s label now includes data supporting its use in hand and foot atopic dermatitis

EU flag

EC opens participation to new alliance addressing critical drug shortages

The Critical Medicines Alliance is expected to publish its first advice by autumn 2024

- PMLiVE

Change? Change!

If you want change in 2024, change in 2024

- PMLiVE

Roche’s subcutaneous Tecentriq granted EC approval for multiple cancer types

The formulation reduces treatment time by around 80% compared to intravenous infusion

- PMLiVE

FDA approves Vertex/CRISPR’s Casgevy gene therapy for beta thalassaemia

The companies estimate that approximately 1,000 patients in the US will be eligible for the one-time treatment

- PMLiVE

Cuttsy+Cuttsy promotes Harriet Karia to managing director

Karia has most recently been serving as the agency's client service director

Genesis Research Group RWD and RWE webinar image

Genesis Research Group RWD / HTA / regulatory / ECA webinar on 15 Feb: reserve your place!

On 15 February 2024, Carole Longson and Allie Sosinsky of Genesis Research Group, a leading global provider of tech-enabled real-world evidence, market access, and HEOR solutions, will present a webinar...

Genesis Research Group

icons related to iconography inside Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why iconography matters…

Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...

Cuttsy + Cuttsy

- PMLiVE

Bringing omnichannel to medical affairs: what do you need to know?

By Frank Fisher

Amiculum

- PMLiVE

MHRA approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

Bayer symbol

Bayer’s non-hormonal menopause drug elinzanetant shows promise in phase 3 studies

Vasomotor symptoms are estimated to affect up to 80% of menopausal women

- PMLiVE

Study reveals Takotsubo syndrome patients failed by current cardiovascular treatments

Takotsubo syndrome patients were found to be as vulnerable to dying as heart attack patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links